Research Peptide CAS NO. 863288-34-0 CJC 1295 DAC

Details:

Description

CJC-1295, also known as CJC-1295 DAC, is a synthetic analogue of growth hormone-releasing hormone (GHRH) growth hormone-releasing factor (GRF), which was developed by ConjuChem. It is a modified form of GRF (1-29), with an improved half-life. CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans. Clinical studies have shown that the administration of CJC-1295 may increase body weight, increase total pituitary RNA and growth hormone. The increase in total pituitary RNA and growth hormone suggests that more growth hormone releasing cells were created.

Specification
Name: CJC-1295 DAC
Synonyms: MPA-Lys30,D-Ala2,Gln8,Ala15,Leu27-GRF (1-29) amide
CAS #: 863288-34-0
Molecular Formula: C165H269N47O46
Molecular Mass: 3367.89 Da (g/mol)
Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) DAC
 

Purity
CJC-1295 DAC has a peptide purity level that exceeds 99.0%. This peptide was synthesized with no additives and is supplied as a white lyophilized (freeze-dried) powder.

Usage
CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

CJC-1295 is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).